Senti Bio's SENTI-202, A First-In-Class Off-The-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results In The Treatment Of Pati

Reuters
28 Apr
April 28 (Reuters) - Senti Biosciences Inc ::
*SENTI BIO’S SENTI-202, A FIRST-IN-CLASS OFF-THE-SHELF LOGIC GATED SELECTIVE CD33 OR FLT3 NOT EMCN CAR NK CELL THERAPY, DEMONSTRATES POSITIVE PRELIMINARY CLINICAL RESULTS IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AML

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 28-APR-202511:00:00.323 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10